DK1189608T3 - Farmaceutisk fremstilling på basis af levodopa, carbidopa og entacapon - Google Patents

Farmaceutisk fremstilling på basis af levodopa, carbidopa og entacapon

Info

Publication number
DK1189608T3
DK1189608T3 DK00944070T DK00944070T DK1189608T3 DK 1189608 T3 DK1189608 T3 DK 1189608T3 DK 00944070 T DK00944070 T DK 00944070T DK 00944070 T DK00944070 T DK 00944070T DK 1189608 T3 DK1189608 T3 DK 1189608T3
Authority
DK
Denmark
Prior art keywords
entacapone
carbidopa
levodopa
pharmaceutical preparation
preparation based
Prior art date
Application number
DK00944070T
Other languages
Danish (da)
English (en)
Inventor
Sari Kallioinen
Lasse Kervinen
Marja Laaksonen
Jarmo Lintulaakso
Mervi Niskanen
Marja Partanen
Marja Ritala
Kari Vahervuo
Matti Virkki
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8554988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1189608(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Application granted granted Critical
Publication of DK1189608T3 publication Critical patent/DK1189608T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK00944070T 1999-06-30 2000-06-29 Farmaceutisk fremstilling på basis af levodopa, carbidopa og entacapon DK1189608T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI991485A FI109453B (fi) 1999-06-30 1999-06-30 Farmaseuttinen koostumus
PCT/FI2000/000593 WO2001001984A1 (en) 1999-06-30 2000-06-29 Levodopa / carbidopa / entacapone pharmaceutical preparation

Publications (1)

Publication Number Publication Date
DK1189608T3 true DK1189608T3 (da) 2003-11-10

Family

ID=8554988

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00944070T DK1189608T3 (da) 1999-06-30 2000-06-29 Farmaceutisk fremstilling på basis af levodopa, carbidopa og entacapon

Country Status (42)

Country Link
US (2) US6500867B1 (ko)
EP (1) EP1189608B1 (ko)
JP (2) JP4204783B2 (ko)
KR (1) KR100905428B1 (ko)
CN (1) CN1168440C (ko)
AR (1) AR033796A1 (ko)
AT (1) ATE245417T1 (ko)
AU (1) AU765932B2 (ko)
BG (1) BG65364B1 (ko)
BR (2) BR0011867A (ko)
CA (1) CA2378469C (ko)
CO (1) CO5180579A1 (ko)
CZ (2) CZ303010B6 (ko)
DE (1) DE60004052T2 (ko)
DK (1) DK1189608T3 (ko)
EA (1) EA004503B1 (ko)
EE (1) EE05473B1 (ko)
ES (1) ES2203495T3 (ko)
FI (1) FI109453B (ko)
FR (1) FR2797587A1 (ko)
GE (1) GEP20043314B (ko)
HK (1) HK1047040B (ko)
HR (1) HRP20020088B1 (ko)
HU (1) HU230395B1 (ko)
IL (1) IL146807A (ko)
IT (1) ITMI20001450A1 (ko)
ME (1) ME00520B (ko)
MX (1) MXPA01013167A (ko)
MY (1) MY127685A (ko)
NO (2) NO330260B1 (ko)
NZ (1) NZ515780A (ko)
PE (1) PE20010399A1 (ko)
PL (1) PL197818B1 (ko)
PT (1) PT1189608E (ko)
RS (1) RS50368B (ko)
SI (1) SI1189608T1 (ko)
SK (1) SK286451B6 (ko)
TR (1) TR200103763T2 (ko)
TW (1) TWI241187B (ko)
UA (1) UA75047C2 (ko)
WO (1) WO2001001984A1 (ko)
ZA (1) ZA200109868B (ko)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition
CA2501345A1 (en) * 2002-10-11 2004-04-22 Depomed Development, Ltd. Gastro-retentive levodopa delivery form
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
US20060241183A1 (en) * 2004-09-28 2006-10-26 Farouk Karoum Compositions and methods of using D-DOPA to treat Parkinson's disease
WO2006051154A1 (en) 2004-11-10 2006-05-18 Orion Corporation Treatment of restless legs syndrome
AU2012216377C1 (en) * 2005-06-08 2013-10-10 Orion Corporation Oral dosage form
WO2006131591A2 (en) * 2005-06-08 2006-12-14 Orion Corporation An entacapone-containing oral dosage form
WO2007002516A2 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
KR101370280B1 (ko) * 2005-07-26 2014-03-06 바이알 - 포르텔라 앤드 씨에이 에스에이 Ｃｏｍｔ 억제제로서의 니트로카테콜 유도체
WO2007016190A2 (en) * 2005-07-28 2007-02-08 Duke University Antiparkinsonian action of phenylisopropylamines
EP1948153A2 (en) * 2005-09-21 2008-07-30 Orion Corporation Treatment of symptoms of parkinson`s disease
WO2007056570A2 (en) * 2005-11-07 2007-05-18 Teva Pharmaceutical Industries Ltd. Levodopa compositions
US8772346B2 (en) * 2005-11-09 2014-07-08 Torrent Pharmaceuticals Limited Pharmaceutical composition
GB2429645A (en) * 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
CN100384411C (zh) * 2006-03-17 2008-04-30 北京科信必成医药科技发展有限公司 卡左双多巴口腔崩解片
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
US8741342B2 (en) * 2006-10-30 2014-06-03 Wockhardt Research Centre Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008081268A2 (en) * 2006-12-27 2008-07-10 Wockhardt Research Centre Pharmaceutical compositions of entacapone
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
AU2007346018A1 (en) 2007-01-31 2008-08-07 Bial - Portela & Ca, S.A. Dosage regimen for COMT inhibitors
US20110171275A1 (en) * 2007-08-20 2011-07-14 Team Academy Of Pharmaceutical Science Gastroretentive drug delivery system, preparation method and use thereof
EP2293791B1 (en) * 2008-02-06 2011-11-23 Wockhardt Limited Pharmaceutical compositions of entacapone co-micronized with sugar alcohols
EP2252284B1 (en) * 2008-02-06 2011-05-25 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
AR070907A1 (es) 2008-03-17 2010-05-12 Bial Portela & Ca Sa Formas cristalinas de derivado de nitrocatecol
CN102170869A (zh) * 2008-08-22 2011-08-31 沃克哈特研究中心 包含左旋多巴、卡比多巴和恩他卡朋或其盐的单次单位口服剂量药物组合物
MX2011002017A (es) * 2008-08-22 2011-05-19 Wockhardt Research Center Una composicion farmaceutica de liberacion prolongada de entacapona o sus sales.
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
CN102448444B (zh) 2009-04-01 2016-05-25 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
CN102438587B (zh) * 2009-05-19 2015-08-19 神经层有限公司 用于多巴脱羧酶抑制剂连续施用的组合物
JP5718937B2 (ja) * 2009-12-25 2015-05-13 イノファーマックス インコーポレイテッド パーキンソン病を治療するための医薬組成物及びその調製方法
AU2011222856B2 (en) 2010-03-04 2015-10-15 Orion Corporation Use of levodopa, carbidopa and entacapone for treating Parkinson's disease
DE102010023828A1 (de) * 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
AU2011330757B2 (en) * 2010-11-15 2016-05-26 Neuroderm Ltd Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-O-methyl transferase inhibitors and compositions for same
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012147099A1 (en) * 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
BR112013027219A2 (pt) * 2011-04-26 2016-12-27 Innopharmax Inc composição de entacapone, processo para preparar a composição de entacapone, composição farmacêutica, e, uso da composição de entacapone
DK2791134T3 (da) 2011-12-13 2019-12-09 BIAL PORTELA & Cª S A Kemisk forbindelse, der er anvendelig som mellemprodukt til fremstilling af en catechol-o-methyltransferasehæmmer
TR201204839A2 (tr) * 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
NZ703341A (en) 2012-06-05 2016-11-25 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
RU2677278C2 (ru) * 2013-03-13 2019-01-16 Неуродерм Лтд Способ лечения болезни паркинсона
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
DK3116475T3 (da) 2014-03-13 2020-12-07 Neuroderm Ltd Dopa-decarboxylasehæmmersammensætninger
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
WO2016036308A1 (en) 2014-09-04 2016-03-10 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
WO2016101969A1 (en) 2014-12-23 2016-06-30 Pharmathen S.A. Levodopa/carbidopa/entacapone pharmaceutical preparation and method for preparing the same
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
CN109689036A (zh) * 2016-07-11 2019-04-26 康特拉医药公司 用于治疗早晨运动不能的脉冲药物输送系统
EP3500246B1 (en) 2016-08-18 2021-08-04 Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi Antiparkinson tablet formulation with improved dissolution profile
WO2019145773A1 (en) 2017-12-15 2019-08-01 Nos Life Sciences Corporation Liposomal-encapsulated formulations
IL277553B1 (en) 2018-03-23 2024-07-01 Lobsor Pharmaceuticals Ab Preparations for the treatment of neurodegenerative diseases by continuous administration
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
US6599530B2 (en) 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus

Also Published As

Publication number Publication date
EP1189608A1 (en) 2002-03-27
SK19232001A3 (sk) 2002-06-04
ME00520B (me) 2011-10-10
ITMI20001450A1 (it) 2001-12-28
MXPA01013167A (es) 2002-07-02
NO330260B1 (no) 2011-03-14
EE200100716A (et) 2003-02-17
ES2203495T3 (es) 2004-04-16
US6797732B2 (en) 2004-09-28
AU765932B2 (en) 2003-10-02
CN1358090A (zh) 2002-07-10
EE05473B1 (et) 2011-10-17
KR100905428B1 (ko) 2009-06-30
GEP20043314B (en) 2004-02-10
NZ515780A (en) 2004-06-25
BRPI0011867B1 (pt) 2019-01-08
CN1168440C (zh) 2004-09-29
JP2008156373A (ja) 2008-07-10
BR0011867A (pt) 2002-03-05
HK1047040B (zh) 2005-04-29
CO5180579A1 (es) 2002-07-30
ZA200109868B (en) 2003-05-28
HK1047040A1 (en) 2003-02-07
CZ20014636A3 (cs) 2002-05-15
AU5830600A (en) 2001-01-22
CA2378469C (en) 2009-10-06
NO20016203D0 (no) 2001-12-18
NO20110090L (no) 2002-02-25
CZ303010B6 (cs) 2012-02-29
RS50368B (sr) 2009-11-10
CA2378469A1 (en) 2001-01-11
TWI241187B (en) 2005-10-11
UA75047C2 (en) 2006-03-15
JP4885896B2 (ja) 2012-02-29
HRP20020088A2 (en) 2005-10-31
US6500867B1 (en) 2002-12-31
CZ304416B6 (cs) 2014-04-23
HUP0202273A3 (en) 2002-11-28
WO2001001984A1 (en) 2001-01-11
JP2003503454A (ja) 2003-01-28
PT1189608E (pt) 2003-12-31
DE60004052T2 (de) 2004-04-15
NO20016203L (no) 2002-02-25
TR200103763T2 (tr) 2002-04-22
JP4204783B2 (ja) 2009-01-07
SK286451B6 (sk) 2008-10-07
FI109453B (fi) 2002-08-15
ITMI20001450A0 (it) 2000-06-28
YU92501A (sh) 2004-09-03
ATE245417T1 (de) 2003-08-15
BG106251A (en) 2002-08-30
AR033796A1 (es) 2004-01-07
PL352775A1 (en) 2003-09-08
US20030017201A1 (en) 2003-01-23
KR20020010155A (ko) 2002-02-02
FI991485A0 (fi) 1999-06-30
PL197818B1 (pl) 2008-04-30
EP1189608B1 (en) 2003-07-23
FI991485A (fi) 2000-12-31
PE20010399A1 (es) 2001-04-10
HU230395B1 (hu) 2016-04-28
IL146807A (en) 2006-10-05
DE60004052D1 (de) 2003-08-28
MY127685A (en) 2006-12-29
EA200200106A1 (ru) 2002-06-27
SI1189608T1 (en) 2004-04-30
HUP0202273A2 (en) 2002-10-28
EA004503B1 (ru) 2004-04-29
HRP20020088B1 (en) 2007-05-31
BG65364B1 (bg) 2008-04-30
BRPI0011867B8 (pt) 2021-05-25
FR2797587A1 (fr) 2001-02-23

Similar Documents

Publication Publication Date Title
DK1189608T3 (da) Farmaceutisk fremstilling på basis af levodopa, carbidopa og entacapon
DK1131301T3 (da) 2-phenylbenzimidazoler og 2-phenylindoler, fremstilling af anvendelse heraf
PT1177178E (pt) Benzimidazois hetereciclicos substituidos, sua preparacao e aplicacao
NO975513L (no) 3-hydroksypyridin-2-karboksylsyreamidester, fremstilling og anvendelse som legemiddel
EE200100147A (et) Farmatseutiline koostis, millesse kuuluvad entakapoon või nitekapoon ning ristsidemega tselluloosiderivaat
MA26666A1 (fr) Antioxide, composition antiproliferee, y compris carnitine et carotenoide.
DK1043306T3 (da) 3-amino-3-arylpropan-1-ol-derivater, fremstilling og anvendelse af disse
NL1012028A1 (nl) Aminozuursequentie.
ES1040916Y (es) Microterminal perfeccionado.
ES1044794Y (es) Lapida perfeccionada.
FI20011892A0 (fi) Menetelmä entakaponia, levodopaa ja karbidopaa sisältävän farmaseuttisen koostumuksen valmistamiseksi
FI20012162A0 (fi) Koostumus ja menetelmä entakaponia, levodopaa ja karbidopaa sisältävän farmaseuttisen koostumuksen valmistamiseksi
ES1044603Y (es) Preservativo perfeccionado.
ES1039867Y (es) Parrilla asadora perfeccionada.
ES1039265Y (es) Rocodromo perfeccionado.
ES1039438Y (es) Expositor-expendedor perfeccionado.
ES1039871Y (es) Colgante perfeccionado.
DK1127052T3 (da) Substituerede 2-phenylbenzimidazoler, fremstilling og anvendelse heraf
NO981089D0 (no) Epoksy-azetidinoner, fremstilling og anvendelse derav
ES1040319Y (es) Pasador perfeccionado.
ES1041259Y (es) Juguete perfeccionado.
ES1047660Y (es) Chupete perfeccionado.
ES1042593Y (es) Sombrilla perfeccionada.
ES1039298Y (es) Barbacoa perfeccionada.
ES1041478Y (es) Barbacoa perfeccionada.